Matthew R. Smith, J. Manola, D. Kaufman
Oct 1, 2004
Citations
2
Influential Citations
129
Citations
Quality indicators
Journal
Cancer
Abstract
The objective of this study was to assess the biologic activity of rosiglitazone, a peroxisome proliferator‐activated receptor γ agonist that has been approved to treat type 2 diabetes, in men with recurrent prostate carcinoma using change in prostate specific antigen (PSA) doubling time (PSADT) as the primary outcome variable.